Contributory roles of sarcopenia and myosteatosis in development of overt hepatic encephalopathy and mortality after transjugular intrahepatic portosystemic shunt

Table 4 The univariate and multivariable analysis results for predicting mortality in patients treated with transjugular intrahepatic portosystemic shunt

Characteristics	Univariate analysis			Multivariate analysis
	HR	95%CI	P value	HR	95%CI	P value
Age (years)	1.042	(1.008-1.077)	0.016a	1.047	(1.012-1.084)	0.278
Gender (male)	1.187	(0.559-2.518)	0.656
BMI (kg/m2)	1.000	(0.871-1.148)	0.997
Etiology (Viral hepatitis/other)	1.187	(0.559-2.518)	0.656
Ascites (yes/no)	1.652	(0.714-3.823)	0.241
Child-Pugh score	1.317	(1.064-1.630)	0.011a	1.194	(0.903-1.579)	0.740
MELD score	1.089	(1.013-1.172)	0.021a	1.050	(0.963-1.146)	0.845
NLR	1.060	(0.994-1.130)	0.075
TBIL (umol/L)	1.022	(0.996-1.048)	0.096
ALT (U/L)	1.003	(0.986-1.020)	0.745
AST (U/L)	1.007	(0.998-1.016)	0.109
Reduction in PPG (%)	1.030	(0.992-1.069)	0.120
Albumin (g/L)	0.904	(0.836-0.977)	0.011a	0.903	(0.827-0.986)	0.023a
Creatinine (umol/L)	1.012	(1.000-1.024)	0.044a	1.005	(0.993-1.018)	0.342
PMA (HU)	0.887	(0.839-0.938)	< 0.001a	0.901	(0.853-0.951)	< 0.001a
TPMT (mm/m)	0.851	(0.759-0.954)	0.006a	0.867	(0.760-0.988)	0.032a

^aP < 0.05.

BMI: Body mass index; MELD: Model for end-stage liver disease; NLR: Neutrophil-lymphocyte ratio; TBIL: Total bilirubin; ALT: Alanine aminotransferase; AST: Aspartate transaminase; PPG: Portosystemic pressure gradient; PMA: Psoas muscle attenuation; TPMT: Transversal psoas muscle thickness; HU: Hounsfield units.